International Study of Chronic Myeloid Leukemia Treatment and Outcomes in Children and Adolescents Under 18

What this Trial Is About

Researchers are studying chronic myeloid leukemia CML, a rare blood cancer, in children and adolescents under 18 years old. This international observational study aims to better understand the characteristics, treatment approaches, and prognostic factors of pediatric CML. It also seeks to evaluate the long-term effects of treatments, especially tyrosine kinase inhibitors, on growth and development in this young population. The study collects both retrospective and prospective data from medical records and databases, without administering new treatments or interventions. Data gathered include demographic details, diagnosis information, treatment histories, and follow-up outcomes. National coordinating centers in participating countries gather anonymized patient data and send it to a central data center in France for analysis. Participants data are collected and updated twice yearly, with ongoing monitoring to describe patient characteristics and treatment policies. Researchers analyze survival, response to treatment, side effects, and long-term outcomes. The study is expected to continue for about five years, with results shared regularly with participating centers and published anonymously.

International Chronic Myeloid Leukemia Pediatric Study